Clinical Trial Update: Aminocamptothecin in Treating Patients With Refractory or Recurrent Hodgkin's Disease or Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating aminocamptothecin in patients with refractory or recurrent Hodgkin lymphoma or non-Hodgkin lymphoma has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Aminocamptothecin (aminocamptothecin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Lymphoma | Phase 2 | Status: COMPLETED